Factors affecting Intracerebral Hemorrhage following Intravenous Thrombolysis in Patients with Acute Ischemic Stroke

Article Sidebar

PDF
Published: Dec 30, 2016
Keywords:
Acute Ischemic Stroke Intravenous Thrombolysis Risk factor

Main Article Content

สุจริต สวนกูล
ธานินทร์ โลเกศกระวี

Abstract

Background: There is limited information about risk factors of intracerebral hemorrhage (ICH) in patients treated with intravenous recombinant tissue plasminogen activator (IVrt-PA) for stroke fast track program in Thailand.
Objective: To determine factors associated with ICH following IVrtPA in stroke fast track program in Lampang Hospital.
Material and method: Retrospective cohort study was conducted on 391 patients with acute ischemic stroke whom treated with IVrt-PA at emergency department of Lampang Hospital between June 2008 - September 2016. Baseline characteristics, laboratory tests, findings of brain CT scan images were recorded. Risk factors were compared between patients without ICH, asymptomatic ICH and symptomatic ICH by using ordinal logistic regression analysis.
Results : The incidence of ICH was 18.4% (asymptomatic ICH 11.2%, symptomatic ICH 7.2%). Risk factors for ICH were male (RR1.88, 95%CI 1.12-3.16, p=0.017), DM with prior stroke (RR 4.64, 95%CI 1.23-17.50, p=0.023), increasing NIHSS scores (NIHSS 10-20: RR 1.87, 1.00-3.49, p=0.049; NIHSS>20: RR 2.96, 95% CI 1.26-6.95, p=0.013) and systolic blood pressure prior thrombolysis ≥150 mmHg (RR 2.09, 95% CI 1.26-6.95, p=0.004).
Conclusion: Male, DM with prior stroke, severe stroke symptoms and high systolic blood pressure prior thrombolysis were risk factors for ICH among patients with acute ischemic stroke treated with IVrt-PA.

Article Details

How to Cite
สวนกูล ส., & โลเกศกระวี ธ. (2016). Factors affecting Intracerebral Hemorrhage following Intravenous Thrombolysis in Patients with Acute Ischemic Stroke. Lampang Medical Journal, 37(2), 67–77. Retrieved from https://he01.tci-thaijo.org/index.php/LMJ/article/view/185880
Issue
Vol. 37 No. 2 (2016): Vol.37 No.2 July-December 2016
Section
Original Article

บทความที่ส่งมาลงพิมพ์ต้องไม่เคยพิมพ์หรือกำลังได้รับการพิจารณาตีพิมพ์ในวารสารอื่น เนื้อหาในบทความต้องเป็นผลงานของผู้นิพนธ์เอง ไม่ได้ลอกเลียนหรือตัดทอนจากบทความอื่น โดยไม่ได้รับอนุญาตหรือไม่ได้อ้างอิงอย่างเหมาะสม การแก้ไขหรือให้ข้อมูลเพิ่มเติมแก่กองบรรณาธิการ จะต้องเสร็จสิ้นเป็นที่เรียบร้อยก่อนจะได้รับพิจารณาตีพิมพ์ และบทความที่ตีพิมพ์แล้วเป็นสมบัติ ของลำปางเวชสาร

References

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13): 1317-29.
2. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan YY, et al. Part 11: adult stroke: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010; 122(18 Suppl 3): S818-28.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333(24): 1581-7.
4. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37(7): 1810-5.
5. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in strokemonitoring study (SITS-MOST): an observational study. Lancet 2007; 369(9558): 275-82.
6. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009; 40(11): 3591-5.
7. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41(9): 1984-9.
8. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hem orrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012; 43(11): 2904-9.
9. Dharmasaroja PA, Muengtaweepongsa S, Pattaraarchachai J, Dharmasaroja P. Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke. J Clin Neurosci 2012; 19(6): 799-803.
10. Warinthorn P, Kittisak S, Boonrerk S, Somsak T, Kannikar K, Verajit C, et al. Risk factors for intracerebral hemorrhage after treatment with recombinant tissue-type plasminogen activator for acute ischemic stroke. Asian Biomedicine 2015; 9(3): 397-400.
11. Lokeskrawee T, Boonsri C, Nakakul N, Kawong K, Yottou L. Applying the lean production system to improve stroke fast track care in Lampang. Lampang Med J 2012; 33(2): 90-102.